Return on Equity: The amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested. Calculated as: Income from Continuing Operations / Total Common Equity
Kiniksa Pharmaceuticals, Ltd. (KNSA) had Return on Equity of 3.21% for the most recently reported fiscal year, ending 2023-12-31.
Income Statement Financials | |
$270.26M |
|
$14.08M |
|
$33.41M |
|
$236.85M |
|
$295.45M |
|
$-25.20M |
|
$8.54M |
|
$-16.65M |
|
$-16.65M |
|
$14.08M |
|
$14.08M |
|
$14.08M |
|
$14.08M |
|
$-25.20M |
|
$-22.86M |
|
70.06M |
|
71.92M |
|
$0.20 |
|
$0.20 |
|
Balance Sheet Financials | |
$276.30M |
|
$0.73M |
|
$250.03M |
|
$526.32M |
|
$63.67M |
|
-- |
|
$23.82M |
|
$87.48M |
|
$438.84M |
|
$421.59M |
|
$438.84M |
|
70.46M |
|
Cash Flow Statement Financials | |
$13.30M |
|
$-29.56M |
|
$1.50M |
|
$122.72M |
|
$107.95M |
|
$-14.76M |
|
$27.15M |
|
-- |
|
-- |
|
Fundamental Metrics & Ratios | |
4.34 |
|
-- |
|
-- |
|
-- |
|
-- |
|
87.64% |
|
-9.32% |
|
-9.32% |
|
-8.46% |
|
-6.16% |
|
5.21% |
|
$13.17M |
|
-- |
|
-- |
|
-- |
|
0.51 |
|
1.07 |
|
12.71 |
|
28.72 |
|
Return on Equity |
3.21% |
3.34% |
|
2.68% |
|
3.21% |
|
$6.23 |
|
$0.18 |
|
$0.18 |